N1VS34 Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 59.50 |
| 52 Week High | CHF 68.54 |
| 52 Week Low | CHF 47.50 |
| Beta | 0.51 |
| 1 Month Change | -0.63% |
| 3 Month Change | -7.61% |
| 1 Year Change | 23.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 39.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| N1VS34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | -4.6% | -2.7% | -1.8% |
| 1Y | 23.5% | -25.1% | -7.5% |
Return vs Industry: N1VS34 exceeded the BR Pharmaceuticals industry which returned -25.1% over the past year.
Return vs Market: N1VS34 exceeded the BR Market which returned -7.5% over the past year.
Price Volatility
| N1VS34 volatility | |
|---|---|
| N1VS34 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.6% |
Stable Share Price: N1VS34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: N1VS34's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis AG Fundamentals Summary
| N1VS34 fundamental statistics | |
|---|---|
| Market cap | R$1.19t |
| Earnings (TTM) | R$71.34b |
| Revenue (TTM) | R$302.94b |
16.7x
P/E Ratio3.9x
P/S RatioIs N1VS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N1VS34 income statement (TTM) | |
|---|---|
| Revenue | US$49.94b |
| Cost of Revenue | US$12.07b |
| Gross Profit | US$37.87b |
| Other Expenses | US$26.11b |
| Earnings | US$11.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 5.88 |
| Gross Margin | 75.83% |
| Net Profit Margin | 23.55% |
| Debt/Equity Ratio | 69.8% |
How did N1VS34 perform over the long term?
See historical performance and comparison